The goal of the University of Texas M.D. Anderson Cancer Center SPORE in Breast Cancer is to facilitate innovative translational research in the biology, detection, prevention and treatment of breast cancer, leading eventually to elimination of this disease. Our dedicated collaborative researchers will accomplish this goal by effective integration of laboratory, epidemiologic, translational and clinical research, which will lead to changes in clinical practice that will provide innovative prevention and treatment strategies and improve outcome for patients with this disease. M.D. Anderson Cancer Center has made the elimination of breast cancer a priority by dedicating resources to establish the Breast Cancer Research Program (BCRP) whose purpose it is to support research in breast cancer. The BCRP has transcended departmental and institutional lines to form an integrated multidisciplinary research program focused on advancing the detection, diagnosis, treatment, and prevention of breast cancer. The BCRP has made it possible to recruit new investigators to the institution and to support breast cancer research of existing faculty through their support of pilot projects, strengthening the research infrastructure, and supporting new breast cancer research initiatives. The clinicians and scientists included in this application represent multiple departments and areas of expertise. They have been selected for the SPORE program because of their ongoing interest in translational research, their current level of peer-reviewed funding relevant to this application, the quality of their research, and their commitment to work together as a team. The SPORE is led by a senior clinical investigator and a senior laboratory-based researcher, includes three main areas: research, comprised of five main projects; research support, comprised of three cores; and research development, comprised of the Developmental Research Program and the Career Development Program. The three Cores (administrative, biostatistics and data management, and tissue procurement and pathology) are led by investigators with a track record of accomplishment in their chosen field. The individual Cores will provide the support that will assure the completion of the projects. The five projects that comprise the foundation of this proposal are: 1) Determinants of response to therapy and outcomes in breast cancer patients of different ethnic backgrounds 2) Cyclin E as a novel and powerful prognosticator for breast cancer 3) Treatment of metastatic breast cancer with gene modified mesenchymal stem cells 4) PTEN deficiency and trastuzumab resistance and 5) Targeting breast cancer-specific gene therapy. Each project includes both basic and clinical Co-Leaders. Thus, each project's leadership has complementary strengths and areas of expertise that will allow us to work together in the translation of new findings to clinical therapies and screening procedures.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA116199-04
Application #
7498447
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Program Officer
Kuzmin, Igor A
Project Start
2005-09-23
Project End
2010-08-31
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
4
Fiscal Year
2008
Total Cost
$2,180,817
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Nanos-Webb, A; Bui, T; Karakas, C et al. (2016) PKCiota promotes ovarian tumor progression through deregulation of cyclin E. Oncogene 35:2428-40
Jabbour-Leung, Natalie A; Chen, Xian; Bui, Tuyen et al. (2016) Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. Mol Cancer Ther 15:593-607
Lucenay, Kimberly S; Doostan, Iman; Karakas, Cansu et al. (2016) Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. Cancer Res 76:2406-18
Gaur, Sanchaika; Wen, Yunfei; Song, Jian H et al. (2015) Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget 6:29161-77
Wen, Yunfei; Graybill, Whitney S; Previs, Rebecca A et al. (2015) Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res 21:448-59
Qi, Yuan; Liu, Xiuping; Liu, Chang-Gong et al. (2015) Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments. PLoS One 10:e0119230
Guan, Xiaoxiang; Liu, Hongliang; Ju, Jingfang et al. (2015) Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged ? 55 years. Mol Carcinog 54:281-90
Gutierrez-Rubio, S A; Quintero-Ramos, A; Durán-Cárdenas, A et al. (2015) 1236 C/T and 3435 C/T polymorphisms of the ABCB1 gene in Mexican breast cancer patients. Genet Mol Res 14:1250-9
Nodora, Jesse N; Cooper, Renee; Talavera, Gregory A et al. (2015) Acculturation, Behavioral Factors, and Family History of Breast Cancer among Mexican and Mexican-American Women. Womens Health Issues 25:494-500
Wen, Yunfei; Zand, Behrouz; Ozpolat, Bulent et al. (2014) Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 7:488-500

Showing the most recent 10 out of 137 publications